Key result
TEVAR successfully treats asymptomatic type B aortic dissection occurring after neoadjuvant chemoimmunotherapy and lobectomy.
Why the study?
Aortic dissection can emerge during multimodal cancer treatment without typical symptoms or preceding aortic dilatation, motivating this report of a new-onset type B dissection after chemoimmunotherapy and lung resection for small-cell lung cancer.
Case Report (n=1)
No
This case highlights that occult Stanford type B aortic dissection can occur without typical pain or prior aortic dilatation following chemoimmunotherapy and thoracic surgery, underscoring the need for deliberate aortic comparison on serial oncologic CT scans.
Answers are grounded in this paper and cite their sources.
Heightened aortic surveillance may be prudent after neoadjuvant chemoimmunotherapy and lobectomy; extends immune checkpoint inhibitor vascular associations but remains hypothesis-generating.
Background Aortic dissection can emerge during multimodal cancer treatment without typical symptoms or preceding aortic dilatation. We report a new-onset type B dissection detected during postoperative reassessment after chemoimmunotherapy and lung resection for small-cell lung cancer. Case description A 56-year-old woman with cT4N1M0 small-cell lung cancer and radiologically assessed left pulmonary artery involvement received two cycles of adebrelimab, etoposide, and cisplatin, followed by video-assisted thoracoscopic left upper lobectomy. The outside pathology report described a major pathological response, negative margins, and no tumor in 24 examined lymph nodes. Contrast-enhanced computed tomography (CT) 28 days after surgery revealed a Stanford type B aortic dissection with focal adventitial discontinuity, without documented chest or back pain. Neither pretreatment nor preoperative imaging showed a definite dissection. Concern for rupture prompted thoracic endovascular aortic repair. The intimal entry tear was excluded, and the patient was discharged three days later. Adebrelimab was administered on September 13, 2026, followed by etoposide and cisplatin beginning on September 14. Follow-up contrast-enhanced CT of the thoracic, abdominal, and pelvic vessels was obtained on October 10, 2026. Conclusion This case documents new-onset type B aortic dissection during multimodal treatment for small-cell lung cancer, despite a marked tumor response and no typical aortic symptoms. The focal adventitial discontinuity near the reported operative field makes local perioperative injury a leading consideration. Direct comparison of the aorta on serial oncologic computed tomography should form part of postoperative reassessment; new structural abnormalities warrant prompt vascular evaluation.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) conducted a case report in Small-cell lung cancer (cT4N1M0, stage IIIA) complicated by new-onset Stanford type B aortic dissection (n=1). Neoadjuvant chemoimmunotherapy (adebrelimab, etoposide, cisplatin), video-assisted thoracoscopic left upper lobectomy, and thoracic endovascular aortic repair (TEVAR) was evaluated on Asymptomatic new-onset Stanford type B aortic dissection and clinical response after TEVAR. Neoadjuvant chemoimmunotherapy and left upper lobectomy were followed by an asymptomatic Stanford type B aortic dissection 28 days post-surgery, which was successfully treated with TEVAR.
Synapse has enriched 10 related papers. Consider them for comparative context: